SCARA5 deficiency inhibits ferroptosis via regulating iron homeostasis and results in sorafenib resistance in hepatocellular carcinoma. (PubMed, Cell Signal) - Feb 16, 2025 - "In this study, we found that SCARA5-deficient cells, including mouse embryonic fibroblasts (MEFs) and HCC cells, exhibited reduced sensitivity to ferroptosis induced by erastin and RSL3. Furthermore, we found that SCARA5 deficiency contributed to the resistance of HCC cells to sorafenib, a therapeutic agent for HCC, possibly by inhibiting ferroptosis. Collectively, our study revealed the role of SCARA5 in regulating ferroptosis, providing a profound understanding of sorafenib resistance in HCC systemic therapy."
Journal • Hepatocellular Cancer • Oncology • Solid Tumor
|
|
Cong Chen; Lan Wang; Lin Li; Na Wang; Shi-Hao Bai; Xiao-Fang Cui; Xu-Yang Shang; Ze-Guang Han
|